Scientists track tumor evolution under immune attack in tiny study
NCT ID NCT02724488
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study looks at how tumors evolve when treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers will take blood samples and tumor biopsies from 14 people with advanced head and neck cancer or melanoma to track genetic changes. The goal is to understand why some tumors become resistant to treatment, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand why some tumors stop responding to immune therapies, potentially guiding future treatment strategies.
- What could go wrong
- This is a very small, early-stage observational study with only 14 participants, so results may not apply broadly. It is designed to gather knowledge, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?